

Supprelin® LA (histrelin acetate subcutaneous implant)

When requesting Supprelin® LA (histrelin acetate subcutaneous implant), the individual requiring treatment must be diagnosed with the following FDA-approved indication or an approved off-label compendial use and meet the specific coverage guidelines.

FDA-Approved Indication

Supprelin® LA (histrelin acetate subcutaneous implant) is indicated for the treatment of children with central precocious puberty.

Approved Non-oncology Off-label Compendial Uses

Gender-dysphoric/gender-incongruent individuals; individuals undergoing gender reassignment

Coverage Guidelines

The individual has one of the following indications for approval:

- Central precocious puberty

OR

- Gender-dysphoria/gender-incongruence OR is undergoing gender reassignment; AND
- Supprelin LA is prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of transgender patients

Approval duration: 12 months

Recommended Dosing

The recommended dose is one 50 mg implant inserted subcutaneously in the upper arm once every 12 months.

References

1. Supprelin® LA [prescribing information]. Malvern, PA; Endo Pharmaceuticals Solutions Inc., September 2025.
2. Eugster EA. Treatment of central precocious puberty. *J Endo Soc.* 2019;3:965-972.
3. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics.* 2009 Apr;123(4):e752-62.
4. Krishna KB, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. *Horm Res Paediatr.* 2019;91:357-372.
5. Spack NP. Management of transgenderism. *JAMA.* 2013;309:478-484.
6. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guidelines. *J Clin Endocrinol Metab.* 2017;102:3869-3903.

7. World Professional Association for Transgender Health (WPATH). Standards of Care for the health of transgender and gender diverse people (version 8). Available at: [Standards of Care for the Health of Transgender and Gender Diverse People, Version 8 \(tandfonline.com\)](https://www.tandfonline.com/doi/full/10.1080/17513758.2016.1198878). Accessed on August 10, 2026.
8. Rosenthal SM. Approach to the patient: transgender youth: endocrine considerations. *J Clin Endocrine Metab.* 2014;99:4379-4389.